Percutaneous Tracheostomy in Respiratory Failure Due to COVID-19.


Journal

Journal of bronchology & interventional pulmonology
ISSN: 1948-8270
Titre abrégé: J Bronchology Interv Pulmonol
Pays: United States
ID NLM: 101496866

Informations de publication

Date de publication:
01 Apr 2022
Historique:
received: 25 02 2021
accepted: 30 06 2021
pubmed: 5 8 2021
medline: 25 3 2022
entrez: 4 8 2021
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) can lead to hypoxemic respiratory failure resulting in prolonged mechanical ventilation. Typically, tracheostomy is considered in patients who remain ventilator dependent beyond 2 weeks. However, in the setting of this novel respiratory virus, the safety and benefits of tracheostomy are not well-defined. Our aim is to describe our experience with percutaneous tracheostomy in patients with COVID-19. This is a single center retrospective descriptive study. We reviewed comorbidities and outcomes in patients with respiratory failure due to COVID-19 who underwent percutaneous tracheostomy at our institution from April 2020 to September 2020. In addition, we provide details of our attempt to minimize aerosolization by using a modified protocol with brief periods of planned apnea. A total of 24 patients underwent percutaneous tracheostomy during the study. The average body mass index was 33.0±10.0. At 30 days posttracheostomy 17 (71%) patients still had the tracheostomy tube and 14 (58%) remained ventilator dependent. There were 3 (13%) who died within 30 days. At the time of data analysis in November 2020, 9 (38%) patients had died and 7 (29%) had been decannulated. None of the providers who participated in the procedure experienced signs or symptoms of COVID-19 infection. Percutaneous tracheostomy in prolonged respiratory failure due to COVID-19 appears to be safe to perform at the bedside for both the patient and health care providers in the appropriate clinical context. Morbid obesity did not limit the ability to perform percutaneous tracheostomy in COVID-19 patients.

Sections du résumé

BACKGROUND BACKGROUND
Coronavirus disease 2019 (COVID-19) can lead to hypoxemic respiratory failure resulting in prolonged mechanical ventilation. Typically, tracheostomy is considered in patients who remain ventilator dependent beyond 2 weeks. However, in the setting of this novel respiratory virus, the safety and benefits of tracheostomy are not well-defined. Our aim is to describe our experience with percutaneous tracheostomy in patients with COVID-19.
MATERIALS AND METHODS METHODS
This is a single center retrospective descriptive study. We reviewed comorbidities and outcomes in patients with respiratory failure due to COVID-19 who underwent percutaneous tracheostomy at our institution from April 2020 to September 2020. In addition, we provide details of our attempt to minimize aerosolization by using a modified protocol with brief periods of planned apnea.
RESULTS RESULTS
A total of 24 patients underwent percutaneous tracheostomy during the study. The average body mass index was 33.0±10.0. At 30 days posttracheostomy 17 (71%) patients still had the tracheostomy tube and 14 (58%) remained ventilator dependent. There were 3 (13%) who died within 30 days. At the time of data analysis in November 2020, 9 (38%) patients had died and 7 (29%) had been decannulated. None of the providers who participated in the procedure experienced signs or symptoms of COVID-19 infection.
CONCLUSION CONCLUSIONS
Percutaneous tracheostomy in prolonged respiratory failure due to COVID-19 appears to be safe to perform at the bedside for both the patient and health care providers in the appropriate clinical context. Morbid obesity did not limit the ability to perform percutaneous tracheostomy in COVID-19 patients.

Identifiants

pubmed: 34347696
doi: 10.1097/LBR.0000000000000800
pii: 01436970-202204000-00006
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

125-130

Informations de copyright

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure: There is no conflict of interest or other disclosures.

Références

Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782–793.
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069.
Mallick A, Bodenham AR. Tracheostomy in critically ill patients. Eur J Anaesthesiol. 2010;27:676–682.
Lamb CR, Desai NR, Angel L, et al. Use of Tracheostomy During the COVID-19 Pandemic: American College of Chest Physicians/American Association for Bronchology and Interventional Pulmonology/Association of Interventional Pulmonology Program Directors Expert Panel Report. Chest. 2020;158:1499–1514.
McGrath BA, Brenner MJ, Warrillow SJ, et al. Tracheostomy in the COVID-19 era: global and multidisciplinary guidance. Lancet Respir Med. 2020;8:717–725.
Schultz MJ, Teng MS, Brenner MJ. Timing of tracheostomy for patients with COVID-19 in the ICU—setting precedent in unprecedented times. JAMA Otolaryngol Head Neck Surg. 2020;146:887–888.
Heyd CP, Desiato VM, Nguyen SA, et al. Tracheostomy protocols during COVID-19 pandemic. Head Neck. 2020;42:1297–1302.
Freeman BD, Isabella K, Lin N, et al. A meta-analysis of prospective trials comparing percutaneous and surgical tracheostomy in critically ill patients. Chest. 2000;118:1412–1418.
Angel L, Kon ZN, Chang SH, et al. Novel percutaneous tracheostomy for critically ill patients with COVID-19. Ann Thorac Surg. 2020;110:1006–1011.
Chao TN, Harbison SP, Braslow BM, et al. Outcomes after tracheostomy in COVID-19 patients. Ann Surg. 2020;272:e181–e186.
Long SM, Chern A, Feit NZ, et al. Percutaneous and open tracheostomy in patients with COVID-19: comparison and outcomes of an institutional series in New York City. Ann Surg. 2021;273:403–409.
Chow VLY, Chan JYW, Ho VWY, et al. Tracheostomy during COVID-19 pandemic-novel approach. Head Neck. 2020;42:1367–1373.
Obata K, Miyata R, Yamamoto K, et al. Tracheostomy in patients with COVID-19: a single-center experience. In Vivo. 2020;34:3747–3751.
Kim EJ, Yoo EH, Jung CY, et al. Experience of percutaneous tracheostomy in critically ill COVID-19 patients. Acute Crit Care. 2020;35:263–270.
Krishnamoorthy S, Polanco A, Coleman N, et al. The safety and efficacy of tracheostomy in patients diagnosed with COVID-19: an analysis of 143 patients at a major NYC medical center. Ann Surg. 2020. [Epub ahead of print].
Mattioli F, Fermi M, Ghirelli M, et al. Tracheostomy in the COVID-19 pandemic. Eur Arch Otorhinolaryngol. 2020;277:2133–2135.
Mishra P, Jedge P, Kaushik M, et al. Our experience of tracheostomy in COVID-19 patients. Indian J Otolaryngol Head Neck Surg. 2022;74:1–4.
Benito DA, Bestourous DE, Tong JY, et al. Tracheotomy in COVID-19 patients: a systematic review and meta-analysis of weaning, decannulation, and survival. Otolaryngol Head Neck Surg. 2021;165:398–405.
Breik O, Nankivell P, Sharma N, et al. Safety and 30-day outcomes of tracheostomy for COVID-19: a prospective observational cohort study. Br J Anaesth. 2020;125:872–879.
Chiesa-Estomba CM, Lechien JR, Calvo-Henríquez C, et al. Systematic review of international guidelines for tracheostomy in COVID-19 patients. Oral Oncol. 2020;108:104844.
Bassi M, Ruberto F, Poggi C, et al. Is surgical tracheostomy better than percutaneous tracheostomy in COVID-19-positive patients? Anesth Analg. 2020;131:1000–1005.
Takhar A, Surda P, Ahmad I, et al. Timing of tracheostomy for prolonged respiratory wean in critically ill coronavirus disease 2019 patients: a machine learning approach. Crit Care Explor. 2020;2:e0279.
Chorath K, Hoang A, Rajasekaran K, et al. Association of early vs late tracheostomy placement with pneumonia and ventilator days in critically ill patients: a meta-analysis. JAMA Otolaryngol Head Neck Surg. 2021;147:450–459.

Auteurs

Samuel E Cohen (SE)

Department of Pulmonary and Critical Care Medicine.
Procedure Center, Cedars-Sinai Medical Center, Los Angeles, CA.

Angelena R Lopez (AR)

Department of Pulmonary and Critical Care Medicine.
Procedure Center, Cedars-Sinai Medical Center, Los Angeles, CA.

Philip K Ng (PK)

Department of Pulmonary and Critical Care Medicine.
Procedure Center, Cedars-Sinai Medical Center, Los Angeles, CA.

Oren A Friedman (OA)

Department of Pulmonary and Critical Care Medicine.

George E Chaux (GE)

Department of Pulmonary and Critical Care Medicine.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH